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Impact of metformin on peak aerobic capacity 
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Carrie G. Sharoff, Stuart R. Chipkin, and Benjamin Goldstein 
Abstract: Individually, exercise and the drug metformin have been shown to prevent or delay type 2 diabetes. Metformin 
mildly inhibits complex I of the electron transport system and may impact aerobic capacity in people exercising while tak­
ing metformin. The purpose of the study was to evaluate the effects of metformin on maximal aerobic capacity in healthy 
individuals without mitochondrial dysfunction. Seventeen healthy, normal-weight men (n = 11) and women (n = 6) partici­
pated in a double-blind, placebo-controlled, cross-over design. Peak aerobic capacity was measured twice using a continu­
ous, incrementally graded protocol; once after 7–9 d of metformin (final dose = 2000 mg/d) and once with placebo, with 
1 week between tests. The order of the conditions was counterbalanced. Peak oxygen uptake (VO2 peak), heart rate (HR), 
ventilation (VE), respiratory exchange ratio (RER), rating of perceived exertion (RPE), and test duration were compared 
across conditions using paired t tests with the R statistical program. VO2 peak (–2.7%), peak heart rate (–2.0%), peak ven­
tilation (–6.2%), peak RER (–3.0%), and exercise duration (–4.1%) were all reduced slightly, but significantly, with 
metformin (all p < 0.05). There was no effect of metformin on RPE or ventilatory breakpoint. Correlations between 
the decrement in VO2 peak and any of the other outcome variables were weak (r2 < 0.20) and not significant. Short-
term treatment with metformin has statistically significant, but physiologically subtle, effects that reduce key outcomes 
related to maximal exercise capacity. Whether this small but consistent effect is manifested in people with insulin re­
sistance or diabetes who already have some degree of mitochondrial dysfunction remains to be determined. 
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Re´sume´ : Isole´ment, l’exercice physique et un me´dicament, la metformine, pre´viennent ou retardent l’apparition du dia­
be`te de type 2. La metformine inhibe le´ge`rement le complexe I de la chaıˆne respiratoire et peut avoir un effet sur la capa­
cite´ ae´robie des individus qui font de l’exercice physique. Le but de cette e´tude est d’e´valuer l’effet de la metformine sur 
la puissance ae´robie maximale d’individus en bonne sante´ et sans troubles mitochondriaux. Six femmes et 11 hommes en 
bonne sante´ et de poids normal participent a` une e´tude expe´rimentale a` double insu avec groupe te´moin et inversion des 
groupes. On mesure deux fois la puissance ae´robie de pointe au moyen d’un test d’effort continu d’intensite´ croissante, 
une fois apre`s 7  a` 9 jours de consommation de metformine (dose terminale, 2 000 mg par jour) et l’autre fois, a` sept jours 
d’e´cart, apre`s avoir pris un placebo. L’ordre des se´ances d’e´valuation est contrebalance´. Au moyen du programme 
d’analyse statistique R, on compare par des tests t pour mesures apparie´es les variables suivantes observe´es dans les deux 
conditions : la consommation d’oxyge`ne (VO2) de pointe, la fre´quence cardiaque (HR), le de´bit ventilatoire (VE), le ratio 
d’e´changes gazeux (RER), la perception de l’intensite´ de l’effort (RPE) et la dure´e du test. La metformine suscite des di­
minutions le´ge`res mais significatives (p < 0,05) des variables suivantes : le VO2 de pointe (–2,7 %), la fre´quence cardiaque 
de pointe (–2,0 %), le de´bit ventilatoire de pointe (–6,2 %), le RER de pointe (–3,0 %) et la dure´e du test (–4,1 %). La 
metformine n’au aucun effet sur la RPE et sur le seuil ventilatoire. La corre´lation entre la diminution du VO2 de pointe et 
n’importe laquelle des autres variables est faible et non significative (r2 < 0,20). L’administration a` court terme de la met­
formine suscite des effets significatifs, mais faibles sur les variables associe´es a` la capacite´ d’effort ae´robie. Il reste a` de´­
terminer si ces effets manifestes quoique faibles s’observent chez des individus insulinore´sistants ou souffrant du diabe`te, 
mais qui ont des troubles mitochondriaux. 
Mots-cle´s :  pre´diabe`te, diabe`te de type 2, exercice physique, biguanide. 
[Traduit par la Re´daction] 
Introduction	 and other similar interventions show that lifestyle interven­
tion (i.e., modification of diet and physical activity) is re-
The results from the Diabetes Prevention Program (DPP) markably effective in preventing and (or) delaying the 
transition from insulin resistance to diabetes. (Knowler et 
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(Knowler et al. 2002; Orchard et al. 2005). In addition to 
being one of the most commonly prescribed drugs to treat 
individuals with overt diabetes, metformin is also increas­
ingly prescribed before the diagnosis of diabetes to forestall 
the transition to diabetes in high-risk individuals (Anderson 
2005; De Lusignan et al. 2005; Matthaei et al. 2000). Indi­
viduals prescribed metformin are also encouraged to be 
physically active. For many overweight or obese men and 
women, the additive effects of increased physical activity 
and metformin can be viewed as a promising combination 
therapy. 
Several in vitro studies have shown that metformin has an 
inhibitory effect on the activity of complex I (transfer of 
electrons from NADH to coenzyme Q10) of the mitochondrial 
electron transport system (Batandier et al. 2006; El-Mir et al. 
2000; Guigas et al. 2004; Leverve et al. 2003; Owen et al. 
2000). Inhibition of complex I may slow the transfer of re­
ducing equivalents from the tricarboxylic acid cycle and po­
tentially limit the capacity for oxidative metabolism 
(although there is some reserve mitochondrial capacity to 
use oxygen during exercise with large muscle groups). If the 
inhibition of complex I exceeds that extra capacity, the prac­
tical implication would be a lowering of maximal cardiores­
piratory capacity and increased relative intensity at any given 
absolute exercise workload. Perception of effort would be in­
creased; potentially affecting exercise intensity, duration, to­
tal energy expenditure, and behavior. In studies of aerobic 
exercise physiology or behavior, the exercise intensity is al­
most always controlled by scaling it as a percentage of max­
imal aerobic capacity (Braun et al. 2004; Goodpaster et al. 
2002; Houmard et al. 2004; Musi and Goodyear 2006). If 
metformin treatment lowers peak oxygen uptake (VO2 peak), 
correct comparison of any outcome variables between the 
metformin and placebo groups will be confounded by the dif­
ferent relative exercise intensity in each condition. 
Several laboratory groups are conducting research studies 
in which the addition of exercise to metformin therapy is 
being tested for efficacy in improving glucose metabolism 
(Hallsten et al. 2002; Smith et al. 2007; Tang and Reed 
2001), as well as non-glycemic targets such as microvascu­
lar function (Jadhav et al. 2006) and cardiovascular indices 
in patients with HIV (Driscoll et al. 2004). The converse, 
whether treatment with metformin impacts exercise capacity, 
has not been considered in any systematic way. The ques­
tion is relevant because a reduction in VO2 peak caused by 
metformin may affect functional exercise capacity and im­
pact compliance with physical activity guidelines. 
Therefore, it is important from both a clinical and experi­
mental perspective to understand whether or not treatment 
with metformin affects exercise capacity. The purpose of 
the present study was to assess whether short-term treatment 
with the typical clinical dose of metformin impacted maxi­
mal oxygen consumption and related variables (e.g., maxi­
mal ventilation (VE), heart rate (HR), respiratory exchange 
ratio (RER), etc.) relative to a placebo. To understand the 
effects of metformin uncomplicated by the dysfunction in 
mitochondria or oxidative metabolism that is strongly 
associated with insulin resistance and type 2 diabetes 
(Regensteiner et al. 1998; Lowell and Shulman 2005; Ritov 
et al. 2005), the study was conducted in healthy people with 
normal glucose metabolism. 
Materials and methods 
Overview 
The study was conducted using a longitudinal, placebo-
controlled design in which subjects served as their own con­
trols. Subjects performed a test of peak aerobic capacity 
twice; once while treated with metformin (1000 mg, twice 
daily) and once with placebo. There were 7 days between 
tests to allow sufficient washout of metformin (the half-life 
for elimination of metformin is 2–6 h). The order in which 
the treatment of placebo and metformin conditions were 
completed was counterbalanced across subjects. VO2 peak 
and related variables (e.g., VE, HR, RER, etc.) were com­
pared across the metformin and placebo conditions. 
Subjects 
A convenience sample of 18 locally available non-diabetic 
men (n = 11) and women (n = 7) participated in the study 
(Table 1). All subjects signed an informed consent docu­
ment and completed a physical activity readiness question­
naire and a health history prior to initiating testing. All 
subjects were in good overall health, normal weight or 
overweight, but not obese (body mass index (BMI) = 21–29), 
and did not use tobacco products or take any medications 
(e.g., other antihyperglycemic agents, statin drugs, beta-
blockers, diuretics, etc.) or dietary supplements (e.g., chro­
mium, vanadium, niacin, etc.) that could potentially inter­
act with metformin and (or) maximal cardiorespiratory 
capacity. To maximize the generalizability of the data 
across fitness levels, a mix of relatively sedentary and rec­
reationally active men and women were recruited. The 
study was approved by the Institutional Review Board at 
the University of Massachusetts (Amherst, Mass.) prior to 
initiation of the study. One woman dropped out of the 
study due to gastrointestinal problems in response to the 
pharmacological treatment. Therefore the final sample size 
consisted of 17 subjects (11 men, 6 women). 
Study design 
VO2 peak was determined using an incremental treadmill 
protocol on either a treadmill (Lifestride 9100, Life Fitness, 
Schiller Park, Ill.) or a cycle Ergometer (Sensormedics 800, 
Yorba Linda, Calif.) according to subject preference. For 
each individual subject, the placebo and metformin tests 
were always conducted at the same time of day, with no ex­
ercise for 24 h and no food for 3 h before each test. Testing 
commenced at a relatively easy submaximal workload that 
was scaled to each subject’s fitness or training status (range 
of 50–150 W on the cycle ergometer and 4–6 miles/h 
(1 mile = 1.6 km) at 0% grade on the treadmill). Either the 
cycle resistance (25–50 W increments in early stages; 25 W 
increments as test progressed beyond first few stages) or 
treadmill grade (+2% increments) was increased every 
2 min until a maximal voluntary effort was achieved. Respi­
ratory gases from collected air were measured using the 
TrueMax2400 Metabolic Measurement System (Parvo­
medics, Salt Lake City, Utah). Heart rate was monitored 
throughout testing using a Polar Advantage Heart Rate Mon­
itor (Polar Inc., Lake Success, N.Y.). Fifteen seconds before 
the end of each stage, a systemic rating of perceived exer­
tion (RPE) was assessed by having subjects point to a num­
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Table 1. Subject characteristics (n = 17). 
Mean±SD 
Age (y) 
27.9±3.3 
Height (cm) 
174.0±9.2 
Body mass (kg): 
placebo 
71.2±15.1 
Body mass (kg): 
metformin 
71.1±14.4 
BMI (kg�m–2) 
24.1±3.6 
Note: Descriptive data shown are mean and standard deviation for 11 men and 6 women who completed the 
study. 
ber on a visual ordinal scale ranging from 6 (no exertion at 
all) to 20 (maximal exertion). Oxygen consumption was 
considered peak upon attainment of at least 2 of the follow­
ing 3 criteria: increase in VO2 less than 150 mL despite in­
creased workload, RER > 1.10, and HR within 15 beats�min–1 
of age-predicted maximal heart rate (HRmax = 220 – age (in 
years)). Ventilatory breakpoint (VBP), the first inflection 
point at which ventilation increases more rapidly than oxygen 
consumption (sometimes referred to as ‘‘anaerobic thresh­
old’’), was estimated visually from the relationship between 
VO2 and VE and the relationship between VCO2 and VE. 
When the two relationships are plotted on the same axes, the 
point at which the 2 curves reach a crossing point is defined 
as the VBP (BroÞaitiene¨ and Jakumaite¨ 2002; Cohen-Solal et 
al. 1991). One individual, blinded to the experimental condi­
tions, estimated the VBP for each subject in each experimen­
tal condition. 
Metformin and placebo treatment 
Metformin treatment began at 500 mg/d and was in­
creased every second day to reach the standard clinical 
dose, 1000 mg twice daily. In most subjects, this dose was 
attained on day 5 or 6, but in men or women who experi­
enced gastrointestinal symptoms (n = 3), the ramp-up period 
was extended for up to 3 more days. Once attaining the final 
dosage, all subjects continued on that dose for 3 consecutive 
days. Placebo treatment was identical but all subjects were 
able to reach the final dose on day 5. Although it was de­
signed to be a double-blind protocol, the presence of a met­
allic taste in the mouth and (or) gastrointestinal symptoms 
alerted several subjects (these side-effects were listed in the 
informed consent document as per IRB requirements) and 
the investigators to which treatment was being given. De­
spite this limitation, only a few subjects were reasonably 
certain which treatment they had been given and several 
were convinced they had metformin when they actually had 
the placebo. 
Statistical analysis 
Data are presented as condition mean, the difference be­
tween conditions, 95% confidence interval of that differ­
ence, and exact p value except where noted. Statistical 
significance of the differences between conditions was 
tested using Student’s paired t test. The � level was set at 
0.05. Correlations between outcome variables of interest 
were assessed using Pearson product–moment correlation. 
Results 
VO2, HR, VE,RER, and RPE over time are shown in 
Figs. 1a–1e). For the initial 11 min of the test, the slope of 
the relationships between outcome and time were virtually 
indistinguishable in the metformin and placebo conditions. 
After this point, unequal sample sizes (due to subjects end­
ing the test at different times in the metformin or placebo 
conditions) limit direct comparison by time. VO2 peak, how­
ever, whether assessed in absolute volume or scaled to body 
mass, was slightly (–2.7%) but significantly lower with met­
formin treatment compared with placebo (Table 2). Relative 
to placebo, VO2max on metformin was lower in 12 of 17 sub­
jects, unchanged in 3, and higher in 2. Similarly, peak HR 
(–2.0%), VE (–6.2%), and RER (–3.0%) were all reduced 
slightly in the metformin condition (Table 2). Subjects 
were unable to continue exercising after 13 min 56 s in the 
metformin condition compared with 14 min 31 s with pla­
cebo (–4.1%). Nine of the 17 subjects attained a higher 
workload during the placebo test (+30 W or +2% grade) 
relative to the metformin test. 
Although all of the outcome variables declined signifi­
cantly in the metformin condition, correlations between 
the change in maximal oxygen consumption and any other 
outcome variable were very weak with correlation coeffi­
cients all r2 < 0.20 and p > 0.30. The magnitude of the 
change in VO2 peak induced by metformin was also not 
strongly correlated with cardiorespiratory fitness, i.e., the 
baseline VO2 peak measured in millilitres per kilogram per 
minute (mL�kg–1�min–1). To better understand the relation­
ships, we compared 9 metformin ‘‘responders’’, defined as 
individuals in whom VO2 peak declined by more than 
1.5 mL�kg–1�min–1 (mean = –3.5 mL�kg–1�min–1) when 
taking metformin; with 6 ‘‘non-responders’’: defined as in­
dividuals in whom VO2 peak declined by less than 
0.5 mL�kg–1�min–1 (mean = +0.1 mL�kg–1�min–1) when tak­
ing metformin. There were no significant differences in the 
decrement in maximal HR (–6.4 beats�min–1 for responders 
vs. –5.0 beats�min–1 for non-responders), ventilation 
(–9.9 L�min–1 for responders vs. –7.8 L�min–1 for non-
responders), or test duration (–32 s for responders vs. –49 s 
for nonresponders). Similarly, of 8 subjects who reached a 
lower maximal workload when taking metformin, VO2 peak 
was lower (>1.0 mL�kg–1�min–1) in only 5. Conversely, in 
9 subjects who reached the same maximal workload when 
taking metformin, VO2 peak was depressed by more than 
1 mL�kg–1�min–1 in 6 of them. 
Estimated ventilatory breakpoint occurred at almost exactly 
the same VO2 in both conditions (data not shown). Because 
VO2 peak was lower with metformin, estimated VBP occurred 
at a slightly higher %VO2 peak with metformin (Table 2), but 
the difference between means was not significant. 
Discussion 
Summary of results 
There was a significant reduction in maximal aerobic ca­
pacity when healthy, normal-weight subjects were tested 
while treated with a typical clinical dose of metformin as 
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Fig. 1. Oxygen consumption (a), heart rate (b), ventilation (c), respiratory exchange ratio (d), and rating of perceived exertion (e) over time 
during the maximal exercise test. Owing to different exercise durations across conditions, the full data set (n = 17) can only be compared 
during minutes 2–11 and at the end of the test. The label ‘‘max’’ denotes the end of the incremental test; mean = 14.52 min for placebo and 
13.92 min for metformin. 
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Physiological relevance 
The decline in maximal cardiorespiratory capacity with 
metformin treatment was statistically significant but, on 
average, physiologically subtle. Although a 3% decline 
might be critical to the performance of an elite endurance 
athlete, it is unlikely to be of concern to the individual doing 
recreational physical activity to enhance health. Some indi­
viduals responded more robustly to the metformin treatment, 
however, with declines in VO2 peak of up to 10%. A decline 
of that magnitude can be the difference between exercising 
below or above the lactate threshold, perceived exertion 
would be noticeably higher, and time to fatigue would be re­
duced. The real-world impact of metformin treatment on ex­
ercise capacity will depend on how the effects manifest over 
time. The antihyperglycemic effects of metformin manifest 
quickly and longer-term treatment does not confer increas­
ing benefits (although metformin-associated weight loss can 
potentiate the direct effects). If the metformin effect on car­
diorespiratory capacity we observed is transient, there may 
be no impairments that last beyond the first week. Con­
versely, if the impact of metformin on cardiorespiratory fit­
ness is maintained or potentiated with longer-term treatment, 
exercise capacity could be impacted more severely. Edu­
cated speculation would be aided by understanding how 
metformin caused the decline in VO2 peak observed in the 
present study. 
Mechanisms 
All of the associated outcomes (maximal HR, VE, test 
duration, etc.) declined similarly, suggesting that individu­
als simply did not exercise ‘‘to their maximum’’ when 
treated with metformin. However, there was no difference 
between conditions in the final workload attained. Further­
more, there were no associations between exercise duration 
and any of the other outcomes. Lastly, maximal HR, VE, 
and exercise duration were not different in the individuals 
who had a large decline in VO2 peak with metformin (de­
cline in VO2 peak > 1.5 mL�kg–1�min–1) vs. those who did 
not (decline < 0.5 mL�kg–1�min–1). To illustrate the point, 
the individual with the largest absolute decline in VO2 peak 
(–6.5 mL�kg–1�min–1) had the same exercise duration and 
reached the same maximal workload on both tests. Con­
versely, the person with the largest decline in duration 
(placebo, 17.27 min; metformin, 15.50 min.) had no change 
in VO2 peak. 
There are several potential explanations for the finding 
that metformin had a slight lowering effect on VO2 peak, HR, 
VE, and RER. According to several studies, all performed 
using in vitro cell systems, metformin could impair VO2 peak 
by inhibiting the mitochondrial electron transport system 
(Batandier et al. 2006; El-Mir et al. 2000; Guigas et al. 
2004; Leverve et al. 2003; Owen et al. 2000). The inhibition 
has been observed in skeletal muscle (Brunmair et al. 2004), 
isolated liver (Batandier et al. 2006; El-Mir et al. 2000; 
Leverve et al. 2003; Owen et al. 2000,) and tumor cells 
(Guigas et al. 2004). Effects of metformin on skeletal 
muscle and (or) cardiac tissue have not been studied to 
date. In liver cells, oxidation of malate or aspartate, but not 
succinate, is impaired, implying that inhibition of mitochon­
drial respiration is specific to complex 1 (Owen et al. 2000). 
In one study, metformin lessened production of reactive 
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oxygen species by reverse electron transport (Batandier et 
al. 2006). Researchers have speculated that the inhibition of 
complex I may not be a pharmacological ‘‘side effect’’, but 
is instead central to the (currently still unclear) metformin 
mechanism of action (Leverve et al. 2003; Owen et al. 
2000). Inhibition of complex I by metformin in skeletal 
muscle could constrain oxygen extraction (manifested as a 
smaller arterial–venous difference in the partial pressure of 
O2 (ppO2)) rather than oxygen delivery (cardiac output). If 
the inhibition were also present in cardiac muscle then de­
livery could also be constrained. There were no associations 
between the changes in VO2 peak and maximal HR or VE; 
even if there were, these gross measurements are inadequate 
to determine whether VO2 peak declines because of limita­
tions on oxygen delivery or extraction. Without assessing 
cardiac output or mitochondrial ppO2, whether lower maxi­
mal HR and VE impair VO2 peak or are a result of the lower 
VO2 peak cannot be determined. 
Inhibition of complex I would also be expected to con­
strain oxidation of TCA cycle-derived reducing equivalents, 
restrict oxidative metabolism of pyruvate and acetyl CoA, 
and increase reliance on glycolytic metabolism to lactate. 
Blood lactate was not measured in the present study, but 
the lactate breakpoint can be estimated (although not neces­
sarily causally related) from the ventilatory breakpoint, the 
inflection point where ventilation rises more steeply than 
oxygen consumption. Again, there was no difference in the 
ventilatory breakpoint, suggesting that the balance between 
oxidative and non-oxidative metabolism was not changed in 
response to metformin. 
Research and clinical implications 
Although the subtle decrements in VO2 peak attributable to 
metformin are unlikely to have important clinical relevance, 
they are germane to study designs that involve exercise and 
metformin treatment. Exercise intensity is usually based on 
a percentage of VO2 peak (Braun et al. 2004; Goodpaster et 
al. 2002; Houmard et al. 2004; Musi and Goodyear 2006), 
therefore researchers need to measure VO2 peak while the 
subject is on metformin or risk incorrectly setting the exer­
cise intensity during the metformin treatment intervention. 
Metformin is prescribed to manage hyperglycemia in indi­
viduals with diabetes and prophylactically to delay the tran­
sition to diabetes for individuals with elevated fasting 
glucose (De Lusignan et al. 2005; Jadhav et al. 2006). The 
healthy subjects used in the present study limits the applica­
tion of the results to clinical populations. Healthy individu­
als were tested to avoid the complication of underlying 
mitochondrial myopathy or the confounding variable of hy­
perglycemia. Whether maximal oxygen consumption would 
change to a greater or lesser extent in people with diabetes 
or insulin resistance is difficult to predict. In general, 
cardiorespiratory fitness is lower in those individuals 
compared to the men and women tested in the current study 
(Regensteiner et al. 1998), but we saw no effects of baseline 
fitness on the magnitude of the observed differences. When 
matched for other confounding variables (e.g., body fat, 
VO2 peak, habitual physical activity) blood glucose uptake 
during exercise is the same between insulin-resistant and 
insulin-sensitive individuals (Braun et al. 2004). To deter­
mine whether the decrement in VO2 peak observed in non­
diabetic individuals will be exaggerated or attenuated in 
those with insulin resistance or diabetes will require explic­
itly testing the effects of metformin on aerobic capacity in 
those individuals. The observation that VO2, VE, HR, and 
RER were not affected by metformin at submaximal work­
loads has clear practical relevance. The results imply that 
exercise capacity is only affected at or near maximal 
workloads. Therefore, it is unlikely that individuals would 
experience any impairment in exercise tolerance at the ex­
ercise intensities experienced by the great majority of rec­
reationally active individuals. 
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